Marta Szajnik
Overview
Explore the profile of Marta Szajnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
2044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dymon M, Ciebiera M, Zgliczynska M, Siergiej M, Kociuba J, Szajnik M
Acta Obstet Gynecol Scand
. 2024 Dec;
PMID: 39641399
Introduction: One of the key challenges regarding the management of twins involves choosing the optimal mode of delivery, which is strongly influenced by the final presentation of both fetuses. In...
2.
Paleczny J, Brozyna M, Dudek B, Woyton A, Chodaczek G, Szajnik M, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139071
Credible assessment methods must be applied to evaluate antiseptics' in vitro activity reliably. Studies indicate that the medium for biofilm culturing should resemble the conditions present at the site of...
3.
Baranska A, Kanadys W, Bogdan M, Stepien E, Barczynski B, Klak A, et al.
J Clin Med
. 2022 Aug;
11(16).
PMID: 36012916
The aim of the report was to determine the effects of soy isoflavones on lumbar spine, femoral neck, and total hip bone mineral density (BMD) in menopausal women. MEDLINE (PubMed),...
4.
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, et al.
Nat Commun
. 2019 Jul;
10(1):3000.
PMID: 31278254
Tumor-driven immune suppression is a major barrier to successful immunotherapy in ovarian carcinomas (OvCa). Among various mechanisms responsible for immune suppression, arginase-1 (ARG1)-carrying small extracellular vesicles (EVs) emerge as important...
5.
Szajnik M, Czystowska-Kuzmicz M, Elishaev E, Whiteside T
Expert Rev Mol Diagn
. 2016 Jun;
16(8):811-26.
PMID: 27268121
Introduction: Ovarian cancer (OvCa) is among the most common types of cancer and is the leading cause of death from gynecological malignancies in western countries. Cancer biomarkers have a potential...
6.
Wen Y, Zand B, Ozpolat B, Szczepanski M, Lu C, Yuca E, et al.
Cell Rep
. 2014 Apr;
7(2):488-500.
PMID: 24703838
Therapeutic upregulation of macroautophagy in cancer cells provides an alternative mechanism for cell death. Prolactin (PRL) and its receptor (PRLR) are considered attractive therapeutic targets because of their roles as...
7.
Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, et al.
Gynecol Obstet (Sunnyvale)
. 2014 Jan;
Suppl 4:3.
PMID: 24466501
Background: In patients with Ovarian Cancer (OvCa) exosomes released by tumor cells are present in the plasma and could be involved in tumor progression. This study examines the association between...
8.
Szajnik M, Szczepanski M, Elishaev E, Visus C, Lenzner D, Zabel M, et al.
Gynecol Oncol
. 2012 Aug;
127(3):587-94.
PMID: 22903146
Objective: 17β-hydroxysteroid dehydrogenase isoform 12 (HSD17B12) overexpression is associated with poor clinical outcome in invasive ductal carcinoma of the breast. Here, we evaluated HSD17B12 overexpression and its activity in ovarian...
9.
Szczepanski M, Szajnik M, Welsh A, Whiteside T, Boyiadzis M
Haematologica
. 2011 May;
96(9):1302-9.
PMID: 21606166
Background: Natural killer cell cytotoxicity is decreased in patients with acute myeloid leukemia in comparison to that in normal controls. Tumor-derived microvesicles present in patients' sera exert detrimental effects on...
10.
Whiteside T, Mandapathil M, Szczepanski M, Szajnik M
Bull Cancer
. 2011 Feb;
98(2):E25-31.
PMID: 21339097
Human tumors utilize many different mechanisms of immunosuppression to prevent immune cells from exercising their antitumor activities. These mechanisms, which enable the tumor to escape from the host immune system...